US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

7.24

+1.1017.92%

Pre-market: 7.21-0.0322-0.44%08:55 EDT

Volume:1.13M

Turnover:7.64M

Market Cap:393.91M

PE:-0.46

High:7.25

Open:6.18

Low:6.17

Close:6.14

Loading ...

Overview Company News Filings

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Alumis Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026

Alumis Inc - Phase 3 Onward Program Ongoing With Topline Data Expected in Q1 2026

THOMSON REUTERS

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating

Sector Update: Health Care Stocks Lower Tuesday Afternoon

MT Newswires Live

Acelyrin Reaffirms Merger Deal With Alumis

MT Newswires Live

REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer

Alumis Inc. Announces Merger with ACELYRIN, Inc.

BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger

Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger

BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

THOMSON REUTERS

Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

THOMSON REUTERS

Press Release: ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Promising Prospects for Alumis Inc.’s TYK2 Inhibitor A-005: Analyst Reiterates Buy Rating with $19 Price Target

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALMS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":7.24,"timestamp":1743537600000,"preClose":6.14,"halted":0,"volume":1125305,"hourTrading":{"tag":"盘前","latestPrice":7.2078,"preClose":7.24,"latestTime":"08:55 EDT","volume":6766,"amount":49057.194236,"timestamp":1743598538862},"delay":0,"floatShares":19951689,"shares":54407327,"eps":-15.598233,"marketStatus":"Pre-Market Trading","change":1.1,"latestTime":"04-02 09:00:34 EDT","open":6.18,"high":7.25,"low":6.17,"amount":7640540.749055,"amplitude":0.175896,"askPrice":7.25,"askSize":1000,"bidPrice":7.1,"bidSize":96,"shortable":3,"etf":0,"ttmEps":-15.598233,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743600600000},"marketStatusCode":1,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":7.24,"preHourTrading":{"tag":"盘前","latestPrice":7.2078,"preClose":7.24,"latestTime":"08:55 EDT","volume":6766,"amount":49057.194236,"timestamp":1743598538862},"postHourTrading":{"tag":"盘后","latestPrice":7.15,"preClose":7.24,"latestTime":"19:56 EDT","volume":35909,"amount":257608.2833,"timestamp":1743551812736},"volumeRatio":0.25769001549164156},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":19951689,"roa":"-87.31%","roe":"-198.66%","lyrEps":-72.082961,"volumeRatio":0.25769001549164156,"shares":54407327,"dividePrice":0,"high":7.25,"amplitude":0.175896,"preClose":6.14,"low":6.17,"week52Low":3.18,"pbRate":"1.51","week52High":13.53,"institutionHeld":0,"latestPrice":7.24,"committee":-0.824818,"eps":-15.598233,"divideRate":0,"volume":1125305,"delay":0,"ttmEps":-15.598233,"open":6.18,"prevYearClose":7.86,"prevWeekClose":5.64,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":4,"twentyDayClose":4.59,"sixtyDayClose":8.22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519887248","title":"ACELYRIN Adopts Limited-Duration Stockholder Rights Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887248","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887248?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"LOS ANGELES, March 13, 2025  -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan .The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value.The Rights Plan is effective immediately and will expire on March 12, 2026.ACELYRIN stockholders do not need to take any further action at this time.Guggenheim Securities, LLC is serving as financial advisor to ACELYRIN and Fenwick & West LLP and Paul Hastings LLP are serving as its legal counsel.ACELYRIN, INC.  is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commerciali","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acelyrin-adopts-limited-duration-stockholder-110000068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLRN","ALMS","BK4007","BK4139"],"gpt_icon":0},{"id":"2518222336","title":"Alumis to Present at Leerink's 2025 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222336","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518222336?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March  10, 2025  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimiz","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039679/0/en/Alumis-to-Present-at-Leerink-s-2025-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","BK4137","HCSG"],"gpt_icon":0},{"id":"2518240407","title":"Alumis Price Target Maintained With a $19.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240407","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518240407?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:49","pubTimestamp":1741607340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 07:49 ET (11:49 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2517419854","title":"BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517419854","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517419854?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:07","pubTimestamp":1741442831,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026March 8 (Reuters) - Alumis Inc ALMS.O:ALUMIS INC - PHASE 3 ONWARD PROGRAM ONGOING WITH TOPLINE DATA EXPECTED IN Q1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250308:nFWN3PR08C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2517441570","title":"Alumis Inc - Phase 3 Onward Program Ongoing With Topline Data Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517441570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517441570?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:03","pubTimestamp":1741442584,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250308:nFWN3PR08C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2517744441","title":"Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517744441","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517744441?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:00","pubTimestamp":1741442400,"startTime":"0","endTime":"0","summary":"ESK-001 is a highly selective, next-generation oral tyrosine kinase 2  inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus. Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0. ESK-001 was generally well-tolerated at one year, with no new safety findings. “We’re excited to see that ESK-001 continues to demonstrate a favorable clinical profile for the potential treatment of moderate-to-severe plaque psoriasis, with the ability to improve clinical outcomes as well as patients’ reported symptoms and quality of life,\" said Dr. Jrn Drappa, Alumis’ Chief Medical Officer. \"We believe in the potential of ESK-001 to fill a critical gap in psoriasis patient care as an oral therapy that is well tolerated and may provide biologic-like clinical responses.\". “These long-term data further support the highly differentiated profile of ESK-001 and reinforce its potent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breaking-esk-001-phase-2-140000841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4523","IFN","ALMS"],"gpt_icon":0},{"id":"2517959961","title":"Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517959961","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517959961?lang=en_us&edition=fundamental","pubTime":"2025-03-05 11:45","pubTimestamp":1741146344,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ALMS stock, giving a Buy rating on March 3. Thomas Smith’s rating is b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-alumis-inc-s-clinical-programs-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-alumis-inc-s-clinical-programs-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2517489600","title":"Sector Update: Health Care Stocks Lower Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2517489600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517489600?lang=en_us&edition=fundamental","pubTime":"2025-03-05 03:00","pubTimestamp":1741114825,"startTime":"0","endTime":"0","summary":"Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the Health Care Select Sector SPDR Fund  shedding 0.4%.The iShares Biotechnology ETF  rose less than 0.1%.In corporate news, Walgreens Boots Alliance  is nearing the completion of a go-private deal with Sycamore Partners for around $10 billion, The Wall Street Journal reported late Monday. Walgreens shares jumped 7.3%.UnitedHealth Group  shares rose 2.2% after a retired federal judge in her role as special master issued a recommendation favoring UnitedHealth to the presiding federal judge in a lawsuit brought by the US Department of Justice, which accused the healthcare company of failing to return money it received via the Medicare Advantage program.Acelyrin  and Alumis  reaffirmed Tuesday their commitment to merge in an all-stock deal, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication of interest is \"not reasonably expected to result in a superior pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1267930730.SGD","LU2361044949.HKD","LU1988902786.USD","LU2552382058.USD","LU1548497426.USD","LU1267930227.SGD","LU2491050154.USD","LU1506573853.SGD","SG9999014906.USD","SLRN","LU2552382215.SGD","SG9999014914.USD","LU0661504455.SGD","IE00BJJMRX11.SGD","LU0321505439.SGD","WBA","LU0316494557.USD","LU0708994859.HKD","LU0417517546.SGD","LU0238689110.USD","LU0310800379.SGD","UNH","LU2236285917.USD","XLV","LU0234572021.USD","LU0820562030.AUD","LU2347655156.SGD","LU0683600562.USD","LU1854103824.USD","LU0795875086.SGD","LU0557290698.USD","IBB","LU0672654240.SGD","LU1778281490.HKD","WBA.AU","LU1291159041.SGD","ALMS","LU0353189763.USD","IE00B19Z3581.USD","IE00BFSS7M15.SGD","LU0211326755.USD","LU1720051017.SGD","LU0823416689.USD","LU1551013342.USD","LU0158827781.USD","LU1261432733.SGD","LU1023059063.AUD","LU0211328371.USD","SG9999014898.SGD","SG9999017495.SGD"],"gpt_icon":1},{"id":"2516608325","title":"Acelyrin Reaffirms Merger Deal With Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608325","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516608325?lang=en_us&edition=fundamental","pubTime":"2025-03-04 23:10","pubTimestamp":1741101018,"startTime":"0","endTime":"0","summary":"Acelyrin (SLRN) and Alumis (ALMS) reaffirmed Tuesday their commitment to merge in an all-stock transaction, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0},{"id":"2516067205","title":"REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516067205","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516067205?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:44","pubTimestamp":1741099479,"startTime":"0","endTime":"0","summary":"REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offerCorrects company name to \"Concentra\" in bullet 3, corrects typographical error in bullet 5** Shares of dru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN1F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CON","SEM","ALMS","SLRN"],"gpt_icon":0},{"id":"2516777456","title":"Alumis Inc. Announces Merger with ACELYRIN, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516777456","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516777456?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:28","pubTimestamp":1741098505,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has shared an update. On March 4, 2025, Alumis Inc. and ACELYRIN, Inc. announced their commitment to merge in an all-stock ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-inc-announces-merger-with-acelyrin-inc-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-inc-announces-merger-with-acelyrin-inc-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2516383674","title":"BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516383674","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516383674?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:07","pubTimestamp":1741097248,"startTime":"0","endTime":"0","summary":"BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis MergerMarch 4 (Reuters) - Alumis Inc ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA475HLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2516674655","title":"Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674655","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674655?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:06","pubTimestamp":1741097208,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biop...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acelyrin-alumis-reaffirm-strategic-financial-rationale-of-proposed-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acelyrin-alumis-reaffirm-strategic-financial-rationale-of-proposed-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","ALMS","SLRN"],"gpt_icon":0},{"id":"2516748486","title":"BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516748486","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516748486?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:06","pubTimestamp":1741097191,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed MergerMarch 4 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND ACELYRIN REAFFIRM STRATEGIC AND FINANCIAL RATIONALE OF PROPOSED ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA48S77V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2516783671","title":"ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516783671","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516783671?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:01","pubTimestamp":1741096860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA149XQ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0},{"id":"2516751671","title":"Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516751671","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516751671?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:01","pubTimestamp":1741096860,"startTime":"0","endTime":"0","summary":"Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet. LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025  -- ACELYRIN, INC.  and Alumis Inc.  today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases.\"The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that stockholders support the planned merger,\" said Mina Kim, Chief Executive Officer of ACELYRIN. \"We chose to enter into the merger agreement with Alumis after a comprehensive assessment of strategic alternatives, and believe this is the best outcome for ACELYRIN stockholders. We're excited about the combined company's potential for significant value creation as a result of its expanded portfolio, strong financial foundation and proven leadership.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4139","BK4007","SLRN"],"gpt_icon":0},{"id":"2516671164","title":"ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516671164","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516671164?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA475HLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2516867175","title":"Press Release: ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516867175","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516867175?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger. All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders. LOS ANGELES, March 04, 2025  -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. .The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0},{"id":"2516347682","title":"Promising Prospects for Alumis Inc.’s TYK2 Inhibitor A-005: Analyst Reiterates Buy Rating with $19 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2516347682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516347682?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:27","pubTimestamp":1741001224,"startTime":"0","endTime":"0","summary":"In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-prospects-for-alumis-inc-s-tyk2-inhibitor-a-005-analyst-reiterates-buy-rating-with-19-price-target?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-prospects-for-alumis-inc-s-tyk2-inhibitor-a-005-analyst-reiterates-buy-rating-with-19-price-target?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2514327978","title":"Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2514327978","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514327978?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:08","pubTimestamp":1740751680,"startTime":"0","endTime":"0","summary":"– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension  study in adults with moderate-to-severe plaque psoriasis –。– Additional Phase 2e-poster presentations to describe patient-reported outcomes, disease biomarker activity and pharmacokinetic data of ESK-001 in psoriasis patients –。“We are pleased to have these Phase 2 OLE data for ESK-001 selected for late-breaking oral and e-poster presentations at the annual AAD meeting and the opportunity to share these important results with the dermatology community,” said Martin Babler, President and Chief Executive Officer of Alumis. \"In addition, as a result of our program execution and the strong interest from patients and clinical investigators, we have accelerated our expected topline Phase 3 clinical data milestone to the first quarter of 2026.”About ESK-001Alumis’ lead clinical candidate, ESK-001, is a highly selective, next-generation oral TYK2 inhibitor that is designed to correct immun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-announces-breaker-psoriasis-presentation-140800310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMS","BK4117","BK4107","BK4007","AFG"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":93}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-04-01","current":-1.135362,"percent":0.868571,"low":-5.220865,"twenty":-3.511116,"median":-2.148731,"eighty":-1.291973,"high":-0.660137,"avg":-2.464398,"sd":1.053891,"marketCap":334060987},"quantilePoints":[{"date":"2024-06-28","current":-5.220865,"twenty":-5.220865,"median":-5.220865,"eighty":-5.220865,"marketCap":881360393},{"date":"2024-07-05","current":-3.577828,"twenty":-4.31182,"median":-3.851156,"eighty":-3.577828,"marketCap":603991092},{"date":"2024-07-12","current":-3.798947,"twenty":-4.001025,"median":-3.825051,"eighty":-3.577828,"marketCap":641319297},{"date":"2024-07-15","current":-3.405847,"twenty":-3.980142,"median":-3.798947,"eighty":-3.577828,"marketCap":574958044},{"date":"2024-08-02","current":-4.08515,"twenty":-4.063676,"median":-3.825051,"eighty":-3.577828,"marketCap":689634611},{"date":"2024-08-09","current":-3.930629,"twenty":-4.063676,"median":-3.914533,"eighty":-3.58397,"marketCap":663549141},{"date":"2024-08-16","current":-3.699952,"twenty":-4.025518,"median":-3.855481,"eighty":-3.617622,"marketCap":699416662},{"date":"2024-08-23","current":-3.709695,"twenty":-3.973459,"median":-3.817957,"eighty":-3.659922,"marketCap":701258562},{"date":"2024-08-30","current":-3.67516,"twenty":-3.943506,"median":-3.741353,"eighty":-3.65762,"marketCap":694730166},{"date":"2024-09-06","current":-3.390241,"twenty":-3.930629,"median":-3.739914,"eighty":-3.608539,"marketCap":640870897},{"date":"2024-09-13","current":-3.240587,"twenty":-3.915649,"median":-3.699952,"eighty":-3.511116,"marketCap":612581180},{"date":"2024-09-20","current":-3.272245,"twenty":-3.914533,"median":-3.679477,"eighty":-3.395997,"marketCap":618565543},{"date":"2024-09-27","current":-3.444923,"twenty":-3.859807,"median":-3.655014,"eighty":-3.33556,"marketCap":651207524},{"date":"2024-10-04","current":-2.886598,"twenty":-3.851156,"median":-3.617387,"eighty":-3.295269,"marketCap":545665119},{"date":"2024-10-11","current":-2.961425,"twenty":-3.850149,"median":-3.577828,"eighty":-3.211808,"marketCap":559809977},{"date":"2024-10-18","current":-3.200296,"twenty":-3.817957,"median":-3.47802,"eighty":-3.18015,"marketCap":604964718},{"date":"2024-10-25","current":-3.444923,"twenty":-3.798947,"median":-3.465068,"eighty":-3.200296,"marketCap":651207524},{"date":"2024-10-31","current":-3.231953,"twenty":-3.752872,"median":-3.462191,"eighty":-3.209506,"marketCap":610949081},{"date":"2024-11-08","current":-3.367218,"twenty":-3.741353,"median":-3.447801,"eighty":-3.218715,"marketCap":636518633},{"date":"2024-11-15","current":-2.144174,"twenty":-3.741353,"median":-3.444923,"eighty":-3.209506,"marketCap":511972947},{"date":"2024-11-22","current":-2.15101,"twenty":-3.739051,"median":-3.433411,"eighty":-3.073089,"marketCap":513605166},{"date":"2024-11-29","current":-2.109995,"twenty":-3.736748,"median":-3.419021,"eighty":-3.008623,"marketCap":503811848},{"date":"2024-12-06","current":-1.964163,"twenty":-3.720056,"median":-3.405847,"eighty":-2.970059,"marketCap":468991158},{"date":"2024-12-13","current":-1.989228,"twenty":-3.703849,"median":-3.378729,"eighty":-2.667081,"marketCap":474975964},{"date":"2024-12-20","current":-1.966442,"twenty":-3.691984,"median":-3.312536,"eighty":-2.153744,"marketCap":469535232},{"date":"2024-12-27","current":-1.916313,"twenty":-3.685521,"median":-3.301025,"eighty":-2.142807,"marketCap":457565620},{"date":"2025-01-03","current":-1.873019,"twenty":-3.682067,"median":-3.286635,"eighty":-2.0626,"marketCap":447228227},{"date":"2025-01-10","current":-1.752253,"twenty":-3.67516,"median":-3.266489,"eighty":-2.0029,"marketCap":418392344},{"date":"2025-01-17","current":-1.775039,"twenty":-3.672282,"median":-3.247782,"eighty":-1.966442,"marketCap":423833077},{"date":"2025-01-24","current":-1.497048,"twenty":-3.658468,"median":-3.227637,"eighty":-1.954138,"marketCap":357456138},{"date":"2025-01-31","current":-1.531227,"twenty":-3.654166,"median":-3.211808,"eighty":-1.919959,"marketCap":365617237},{"date":"2025-02-07","current":-1.501605,"twenty":-3.631778,"median":-3.162882,"eighty":-1.882133,"marketCap":358544284},{"date":"2025-02-14","current":-1.162092,"twenty":-3.62163,"median":-3.070787,"eighty":-1.832004,"marketCap":277477367},{"date":"2025-02-21","current":-1.168928,"twenty":-3.613315,"median":-3.018984,"eighty":-1.784609,"marketCap":279109587},{"date":"2025-02-28","current":-1.064112,"twenty":-3.590112,"median":-2.978693,"eighty":-1.743594,"marketCap":254082217},{"date":"2025-03-07","current":-1.162092,"twenty":-3.577828,"median":-2.970059,"eighty":-1.696654,"marketCap":277477367},{"date":"2025-03-14","current":-1.045883,"twenty":-3.561975,"median":-2.844868,"eighty":-1.612801,"marketCap":249729630},{"date":"2025-03-21","current":-0.660137,"twenty":-3.530406,"median":-2.358363,"eighty":-1.527581,"marketCap":194234157},{"date":"2025-03-28","current":-0.869088,"twenty":-3.513232,"median":-2.153288,"eighty":-1.493402,"marketCap":255714436},{"date":"2025-04-01","current":-1.135362,"twenty":-3.511116,"median":-2.148731,"eighty":-1.291973,"marketCap":334060987}],"updateTime":1743598834980}}}